Dabrafenib
Small molecule
Evidence outlook
Approved: Non-Small Cell Lung Cancer, Melanoma, Glioma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (6)
- BRAF V600E Mutation-Positive Metastatic NSCLC TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test [see Dosage and Administration (2.1)] .
- BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options [see Dosage and Administration (2.1)] .
- BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors TAFINLAR is indicated, in combination with trametinib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options [see Dosage and Administration (2.1)] . This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR) [see Clinical Studies (14.6)] . Continued approval for this indicati
- In combination with trametinib for metastatic NSCLC with BRAF V600 mutation
- Treatment of unresectable melanoma with BRAF mutation
- Initial authorisation (BRAF V600 melanoma); the EPAR now also lists dabrafenib with trametinib for advanced BRAF V600 NSCLC
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01682083 NCT01682083 · Melanoma This was a large, randomized, double-blind, placebo-controlled trial with 438 participants receiving dabrafenib plus trametinib and 432 receiving matching placebos. The hard clinical primary endpoint, relapse-free survival, was met: the combination reduced the risk of relapse or death compared with placebo (hazard ratio 0.47; 95% CI 0.39–0.58; p<0.0001). Registry: NCT01682083 | 3 | Percentage of Participants With Relapse-free Survival (RFS) Events (Approximately 4 years); Relapse-free Survival (RFS) (Approximately 4 years) 2017-06-30 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
View 5 more trials
NCT01597908 NCT01597908 · Melanoma The trial was large and randomized, with vemurafenib as an active comparator, and used overall survival—a hard clinical endpoint—as its primary outcome. The primary comparison favored dabrafenib plus trametinib, but treatment was open-label rather than double-blinded, so the evidence is rated moderate rather than strong. Registry: NCT01597908 | 3 | Overall Survival (OS) (From the date of randomization until date of death due to any cause (up to approximately 6 years)) 2014-04-17 | Overall Survival (OS) (From the date of randomization until date of death due to any cause (up to approximately 6 years)): Dabrafenib Plus Trametinib 26 Months (95% CI 22.1 to 33.8) | Vemurafenib 17.8 Months (95% CI 15.6 to 20.7) | Partial signal | link ↗ |
NCT01584648 NCT01584648 · Melanoma This was a large randomized, quadruple-blind, placebo-controlled trial of 423 participants, and its hard clinical primary endpoint of progression-free survival was met: median PFS was 10.2 months with dabrafenib plus trametinib versus 8.8 months with dabrafenib plus placebo (HR 0.73, 95% CI 0.59–0.91). However, dabrafenib was given in both arms as background treatment, so the primary comparison tested trametinib added to dabrafenib rather than dabrafenib itself. Registry: NCT01584648 | 3 | Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)) 2013-08-26 | Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)): Dabrafenib + Trametinib 10.2 Months (95% CI 8.1 to 12.8) | Dabrafenib + Placebo 8.8 Months (95% CI 5.9 to 9.3) | Partial signal | link ↗ |
NCT01227889 NCT01227889 · Melanoma The study was randomized and actively controlled, but it was open-label; its objective radiographic progression-free survival endpoint favored dabrafenib and was statistically significant (187 dabrafenib participants versus 63 dacarbazine participants). The record does not report a power calculation, so the evidence is considered moderate rather than strong despite the favorable primary result. Registry: NCT01227889 | 3 | Progression-free Survival (PFS) as Assessed by the Investigator (Time interval between the date of randomization and the earlier of the date of disease progression or the date of death due to any cause (up to 9.9 months)); Progression-free Survival (PFS) as Assessed by an Independent Radiologist: Randomized Phase (Time interval between the date of randomization and the earlier of the date of disease progression or the date of death due to any cause (up to 9.9 months)) 2011-12-19 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
Break MB NCT01266967 · Melanoma This phase 2 study was single-arm, non-randomised and open-label, with no placebo or active comparator; all 172 participants received dabrafenib in two cohorts defined by prior local therapy for brain metastases. The primary endpoint was investigator-assessed confirmed intracranial response in participants with BRAF V600E melanoma. Intracranial response occurred in 30 of 74 participants without prior local therapy (41%, p<0.0001) and 24 of 65 with prior local therapy (37%, p<0.0001), each from a one-sample exact test within the cohort. Without a control arm, these response rates cannot show how much of the effect was due to dabrafenib. Registry: NCT01266967 | 2 | Number of Participants With BRAF V600E Mutation-positive Melanoma With Overall Intracranial Response (OIR), as Assessed by the Investigator (From the time of the Baseline assessment until disease progression or end of study treatment (average of 18.3 weeks)) 2011-11 | Number of Participants With BRAF V600E Mutation-positive Melanoma With Overall Intracranial Response (OIR), as Assessed by the Investigator (From the time of the Baseline assessment until disease progression or end of study treatment (average of 18.3 weeks)): GSK2118436 150 mg: No Prior Local Therapy — CR: 4 participants; PR: 26 participants | GSK2118436 150 mg: Prior Local Therapy — CR: 1 participants; PR: 23 participants | Weak signal | link ↗ |
NCT02039947 NCT02039947 · Melanoma The study was non-randomized, open-label, and had no comparator arm; all participants received dabrafenib plus trametinib. Although the investigator-assessed intracranial response rate in the primary cohort was 59% (45/76), the single-arm design does not provide a controlled comparison of dabrafenib’s effect. Registry: NCT02039947 | 2 | Intracranial Response (IR) Rate in Cohort A (From the start of treatment until disease progression or the start of new anti-cancer therapy) 2017-05-12 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (3)
What this study did
What this study did
What this study did
Phase 2 (72)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (17)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (36)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (3)
What this study did
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Competitive landscape
This drug's own stage for Glioma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Dabrafenib: this drug | Approved | Small molecule | BRAF V600E/V600K/V600D (also wild-type BRAF/CRAF) | not yet graded | No reviewed efficacy summary in this indication | |
| Dordaviprone | Approved | Small molecule | Mitochondrial caseinolytic protease P (ClpP), Dopamine D2 receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Temozolomide | Approved | Small molecule | DNA alkylation (O6-guanine) | Partial signal | NCT00626990: Overall survival: adjuvant temozolomide vs none, median 82.3 vs 46.9 months, hazard ratio 0.64 (95% CI 0.52 to 0.79), p<0.0001; concurrent temozolomide vs none, 66.9 vs 60.4 months, hazard ratio 0.97 (95% CI 0.73 to 1.28), p=0.76 (CT.gov posted results). | |
| Tovorafenib | Approved | Small molecule | Kinase Inhibitor | Weak signal | No reviewed efficacy summary in this indication | |
| Trametinib | Approved | Small molecule | MEK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Luvometinib | Phase 3 | Small molecule | MEK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| Safusidenib | Phase 3 | Small molecule | Mutant IDH1 | not yet graded | No reviewed efficacy summary in this indication | |
| Abemaciclib (Verzenio) | Phase 2 | Small molecule | CDK4 and CDK6 | not yet graded | No reviewed efficacy summary in this indication | |
| Olutasidenib | Phase 2 | Small molecule | Mutant IDH1 | not yet graded | No reviewed efficacy summary in this indication | |
| Crelosidenib | Phase 1 | Small molecule | Mutant IDH1 and IDH2 | not yet graded | No reviewed efficacy summary in this indication | |
| Vebreltinib | Phase 1 | Small molecule | MET | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(33 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Dabrafenib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.